J. Fruchart Et Al. , "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation," CARDIOVASCULAR DIABETOLOGY , vol.18, 2019
Fruchart, J. Et Al. 2019. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. CARDIOVASCULAR DIABETOLOGY , vol.18 .
Fruchart, J., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., ... Barter, P. J.(2019). The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. CARDIOVASCULAR DIABETOLOGY , vol.18.
Fruchart, Jean-Charles Et Al. "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation," CARDIOVASCULAR DIABETOLOGY , vol.18, 2019
Fruchart, Jean-Charles Et Al. "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation." CARDIOVASCULAR DIABETOLOGY , vol.18, 2019
Fruchart, J. Et Al. (2019) . "The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation." CARDIOVASCULAR DIABETOLOGY , vol.18.
@article{article, author={Jean-Charles Fruchart Et Al. }, title={The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation}, journal={CARDIOVASCULAR DIABETOLOGY}, year=2019}